The company has not filed an annual or quarterly report since its Q3 FY2018 10-Q, filed Nov 14, 2018. Its latest SEC filing is a SEC STAFF ACTION from Aug 5, 2019.
10-Q for Q3 FY2018, filed Nov 14, 2018
The sections below describe the company as of the FY2017 annual report.
Develops a tablet-and-software product that delivers personalized reminiscence therapy to seniors and people with dementia or social isolation.
10-K for FY2017, filed Apr 2, 2018Dthera Sciences “we,” “us,” “our,” “the Company”, based in San Diego, CA, is a digital therapeutics company focused on developing…View ↗
The first component is the customized hardware tablet (the “Tablet”) that is specifically designed for use by individuals with…View ↗
The ReminX Tablet Software (the “Software”), which drives the use of the Tablet, combines a simplified viewing experience for the end user…View ↗
The company planned to market ReminX directly to family members and caregivers; it also planned a revenue-sharing offer for senior-living and long-term-care operators.
10-K for FY2017, filed Apr 2, 2018
10-Q for Q3 FY2018, filed Nov 14, 2018
−$1.6MView ↗
8-K, filed Feb 22, 2019
On February 22, 2019, Dthera Sciences, a Nevada corporation (the “Company”) entered into an exclusivity agreement (the “Agreement”) with a…View ↗
8-K, filed Aug 23, 2018
Dthera Sciences, a Nevada corporation (the “Company”), announced on August 23, 2018, that the U.S. Food and Drug Administration (the “FDA”)…View ↗
8-K, filed Aug 6, 2018
Dthera Sciences, a Nevada corporation (the “Company”), announced on August 1, 2018, the launch of ReminX™, an…View ↗
From technology licensing to digital therapy
Earlier, the business focused on finding new technologies, acquiring licensing rights and marketing licensed technologies, including an IP search tool. The latest report centers on ReminX, a tablet-and-software product that delivers personalized reminiscence therapy to seniors and people with cognitive decline.
10-K for FY2014, filed Oct 28, 2014 10-K for FY2017, filed Apr 2, 2018
Loading...
